EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Precision Microbial Therapeutics for Infertility: Next‐Generation Probiotics, Engineered Biologics and Translational Pathways

Limiao Li, Lin Feng, Qiang Li, Yue Zhou, Sifan Liu, Huimin Song, Shengnan Kang, Huike Chen, Huifang Cong, Shumin Liu iD

Microbial Biotechnology · 2026

DOI: 10.1111/1751-7915.70330 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Microbial Biotechnology, 2026. Verfasst von Limiao Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: Heilongjiang University of Chinese Medicine, Harbin, China. Hauptthemen laut MEDLINE: Probiotics, Infertility, Biological Products, Biological Therapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 176 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Heilongjiang Province Postdoctoral Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Infertility affects ~1 in 6 people of reproductive age and remains difficult to treat because causes are heterogeneous and diagnostics are incomplete. Recent evidence reframes the female reproductive tract as a low‐biomass but biologically active microbial ecosystem. Dysbiosis, typically loss of protective Lactobacillus species (notably L. crispatus ) with overgrowth of anaerobic pathobionts, is associated with implantation failure and recurrent pregnancy loss. Framing conditions such as chronic endometritis and reproducible low‐ Lactobacillus endometrial profiles as dysbiosis‐related disorders clarifies opportunities for prevention, companion diagnostics and microbiome‐directed therapies. This narrative review contrasts receptive ( Lactobacillus ‐dominant) versus dysbiotic states and summarises mechanisms linking microbiota to fertility: microbial metabolites (lactic acid, short‐chain fatty acids) support epithelial barrier function and immune tolerance, whereas dysbiosis provokes inflammation that impairs implantation. Although observational data consistently associate Lactobacillus dominance with better outcomes, evidence quality is low‐to‐moderate due to retrospective designs, methodological heterogeneity, and a lack of adequately powered, diagnostic‐stratified randomised trials. The review highlights precision microbial therapeutics under development, single‐strain next‐generation probiotics, synthetic consortia, engineered live biotherapeutics, postbiotics, targeted phage/endolysins and vaginal microbiota transplantation, and proposes a diagnostic‐driven roadmap that matches microbiome endotypes and clinical contexts (e.g., preconception vs. immediate embryo transfer) to specific interventions. Regulatory and safety issues for reproductive biologics are also considered. The reproductive microbiome is a promising translational frontier but currently offers a consistent signal rather than definitive proof of benefit. To translate promise into practice requires standardised low‐biomass sampling/reporting, mechanistic validation in human‐relevant models and diagnostic‐stratified randomised trials with staged endpoints, alongside strategies to address engraftment, formulation and regulatory pathways.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProbioticsInfertilityBiological ProductsBiological TherapyPrecision MedicineHumansFemaleMicrobiotaDysbiosisLactobacillusAnimals

Stichwörter der Autor:innen

endometrial dysbiosisengineered live biotherapeuticsfertility/assisted reproductionnext‐generation probioticsreproductive microbiome

Substanzen

Biological Products

Autor:innen und Institutionen

  • Heilongjiang University of Chinese Medicine, Harbin, China.
  • Hunan University of Medicine, Huaihua, China.
  • The First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbi, China.
  • The Second Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbi, China.

ORCID-Profile: Shumin Liu

Förderung

  • Heilongjiang Province Postdoctoral Fund

Zitieren

APA

Li, L., Feng, L., Li, Q., Zhou, Y., Liu, S., Song, H., Kang, S., Chen, H., Cong, H., & Liu, S. (2026). Precision Microbial Therapeutics for Infertility: Next‐Generation Probiotics, Engineered Biologics and Translational Pathways. Microbial Biotechnology. https://doi.org/10.1111/1751-7915.70330

Vancouver

Li L, Feng L, Li Q, Zhou Y, Liu S, Song H, et al. Precision Microbial Therapeutics for Infertility: Next‐Generation Probiotics, Engineered Biologics and Translational Pathways. Microbial Biotechnology. 2026. doi:10.1111/1751-7915.70330

BibTeX
@article{Li2026,
  author = {Li, Limiao and Feng, Lin and Li, Qiang and Zhou, Yue and Liu, Sifan and Song, Huimin and Kang, Shengnan and Chen, Huike and Cong, Huifang and Liu, Shumin},
  title = {Precision Microbial Therapeutics for Infertility: Next‐Generation Probiotics, Engineered Biologics and Translational Pathways},
  journal = {Microbial Biotechnology},
  year = {2026},
  doi = {10.1111/1751-7915.70330}
}
Kostenlos starten →